Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.35 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.35 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL847328 | 1.00 | GABRR1 (0.52) | GABRR1CYP1A2BLMACE2LTA4H | |
| SCHEMBL13368999 | 0.86 | BLM (0.52) | GABRR1CYP1A2BLMACE2LTA4H | |
| SCHEMBL8588686 | 0.86 | BLM (0.52) | GABRR1CYP1A2BLMACE2LTA4H | |
| SCHEMBL8062393 | 0.84 | LTA4H (0.50) | GABRR1CYP1A2BLMACE2LTA4H | |
| SCHEMBL25468996 | 0.84 | LTA4H (0.50) | GABRR1CYP1A2BLMACE2LTA4H | |
| SCHEMBL14610975 | 0.82 | ACE2 (0.50) | GABRR1CYP1A2BLMACE2LTA4H | |
| SCHEMBL8213505 | 0.82 | ACE2 (0.50) | GABRR1CYP1A2BLMACE2LTA4H | |
| SCHEMBL14569702 | 0.82 | ACE2 (0.50) | GABRR1CYP1A2BLMACE2LTA4H | |
| SCHEMBL5139179 | 0.81 | GABRR1 (0.72) | GABRR1CYP1A2BLMACE2LTA4H | |
| SCHEMBL5790691 | 0.80 | CHRNB2 (0.33) | GABRR1CYP1A2HTR2AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118955655-A | GE protein antigen variant, preparation method and application thereof | 北京微星生物科技有限公司 | 2024-11-15 | — | — | CN | claimed |
| WO-2024078534-A1 | INTERFERING RNA FOR INHIBITING EXPRESSION OF MELANOPHILIN (MLPH) GENE, AND APPLICATION THEREOF | 北京键凯科技股份有限公司 | 2024-04-18 | — | — | WO | claimed |
| CN-116322788-A | Cyclic RNA compositions and methods | 奥纳治疗公司 | 2023-06-23 | — | — | CN | claimed |
| CN-115803049-A | Antigen encoding cassette | 磨石生物公司 | 2023-03-14 | — | — | CN | claimed |
| CN-113151312-B | Novel coronavirus SARS-CoV-2mRNA vaccine and its preparation method and application | 中国科学院微生物研究所 | 2022-12-09 | — | — | CN | claimed |
| CN-114272369-A | mRNA vaccine composition for preventing varicella-zoster virus | 中国科学院微生物研究所 | 2022-04-05 | — | — | CN | claimed |
| EP-3364949-A1 | CANCER VACCINES | ModernaTX, Inc. (US) | 2018-08-29 | — | — | EP | claimed |
| EP-3364950-A1 | TROPICAL DISEASE VACCINES | ModernaTX, Inc. (US) | 2018-08-29 | — | — | EP | claimed |
| EP-3324979-A2 | INFECTIOUS DISEASE VACCINES | ModernaTX, Inc. (US) | 2018-05-30 | — | — | EP | claimed |
| WO-2017070624-A1 | TROPICAL DISEASE VACCINES | MODERNATX, INC. (US) | 2017-04-27 | — | — | WO | claimed |
| WO-2017070618-A1 | CANCER VACCINES | MODERNATX, INC. (US) | 2017-04-27 | — | — | WO | claimed |
| US-9278907-B2 | Use of 4-[ethyl(dimethyl)ammonio]butanoate in the treatment of cardiovascular disease | JSC GRINDEKS (LV) | 2016-03-08 | — | — | US | claimed |
| EP-2491005-B1 | USE OF 4-[ETHYL(DIMETHYL)AMMONIO]BUTANOATE IN THE TREATMENT OF CARDIOVASCULAR DISEASE | GRINDEKS JSC (LV) | 2014-07-23 | — | — | EP | claimed |
| CN-102666476-B | Use of 4-[ethyl(dimethyl)ammonio]butanoate in the treatment of cardiovascular disease | GRINDEKS JOINT STOCK COMPANY | 2014-07-09 | — | — | CN | claimed |
| CN-103547562-A | 4- [ (haloalkyl) (dimethyl) ammonio ] butanoates and their use in the treatment of cardiovascular disease | JSC GRINDEKS | 2014-01-29 | — | — | CN | claimed |
| CN-102666476-A | Use of 4-[ethyl(dimethyl)ammonio]butanoate in the treatment of cardiovascular disease | GRINDEKS JSC | 2012-09-12 | — | — | CN | claimed |
| US-20120220656-A1 | USE OF 4-[ETHYL(DIMETHYL)AMMONIO]BUTANOATE IN THE TREATMENT OF CARDIOVASCULAR DISEASE | JSC GRINDEKS (LV) | 2012-08-30 | — | — | US | claimed |
| EP-2491005-A1 | USE OF 4-[ETHYL(DIMETHYL)AMMONIO]BUTANOATE IN THE TREATMENT OF CARDIOVASCULAR DISEASE | Grindeks, A Joint Stock Company (LV) | 2012-08-29 | — | — | EP | claimed |
| WO-2011048201-A1 | USE OF 4-[ETHYL(DIMETHYL)AMMONIO]BUTANOATE IN THE TREATMENT OF CARDIOVASCULAR DISEASE | GRINDEKS, A JOINT STOCK COMPANY (LV) | 2011-04-28 | — | — | WO | claimed |
| CN-120152736-A | Compositions and related methods for delivering plasmodium CSP antigens | 生物技术欧洲股份公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-119768435-A | Compositions and methods | 旗舰先锋创新有限责任VII公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-119604304-A | Recombinant RNA molecules comprising an untranslated region or a segment encoding spike protein from the Severe acute respiratory coronavirus 2 Omikovia strain | 葛兰素史克生物有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-119486753-A | Personalized cancer epitopes and methods of use thereof | 珍诺斯医疗公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-119365486-A | EPO receptor agonists and antagonists | 免疫先锋股份有限公司 | 2025-01-24 | — | — | CN | disclosed |
| CN-118955655-A | GE protein antigen variant, preparation method and application thereof | 北京微星生物科技有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-118946333-A | Methods for preventing and/or treating ocular disorders | 塞拉尼斯伊娃高性能聚合物公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-118922194-A | Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods | 生物技术公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-118647370-A | Implantable device for delivering tyrosine kinase inhibitors | 塞拉尼斯伊娃高性能聚合物公司 | 2024-09-13 | — | — | CN | disclosed |
| CN-118647397-A | Polynucleotide composition and use thereof | 辉瑞公司 | 2024-09-13 | — | — | CN | disclosed |
| CN-118613588-A | SERPINA modulating compositions and methods | 旗舰先锋创新VI有限责任公司 | 2024-09-06 | — | — | CN | disclosed |
| CN-118556123-A | HBB modulating compositions and methods | 旗舰先锋创新VI有限责任公司 | 2024-08-27 | — | — | CN | disclosed |
| CN-118490818-A | Coronavirus vaccine | 生物技术欧洲股份公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-118489007-A | Methods and compositions for modulating genome | 旗舰先锋创新VI有限责任公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-118434756-A | Compositions and methods for ribonucleic acid Respiratory Syncytial Virus (RSV) vaccines | 达冕生物有限公司 | 2024-08-02 | — | — | CN | disclosed |
| EP-4395820-A2 | NOVEL LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS COMPRISING PHOSPHATIDYLSERINE | CureVac SE (DE) | 2024-07-10 | — | — | EP | disclosed |
| US-12031132-B2 | Systems and methods for the treatment of hemoglobinopathies | EDITAS MEDICINE, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| CN-118318041-A | Trans-recruitment of gene editing system components | 旗舰先锋创新VI有限责任公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-117964577-B | Cationic lipid compound, preparation method thereof, composition containing cationic lipid compound and application of cationic lipid compound | 天津全和诚生物技术有限公司 | 2024-06-21 | — | — | CN | disclosed |
| EP-4384214-A2 | COMPOSITION AND METHODS OF MRNA VACCINES AGAINST NOVEL CORONAVIRUS INFECTION | Rnaimmune, Inc. (US) | 2024-06-19 | — | — | EP | disclosed |
| CN-118215738-A | Compositions and methods using purified human RNA editing enzymes | 加利福尼亚大学董事会 | 2024-06-18 | — | — | CN | disclosed |
| CN-118119930-A | Compositions and methods for mRNA vaccines against novel coronavirus infection | 达冕生物有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-118119404-A | Immunogenic LNP compositions and methods thereof | 辉瑞公司 | 2024-05-31 | — | — | CN | disclosed |
| EP-4372090-A2 | CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING GRNAS | Editas Medicine, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| WO-2024102813-A1 | ENGINEERED VARICELLA ZOSTER VIRUS SHINGLES MRNA VACCINE | Vernagen, LLC (US) | 2024-05-16 | — | — | WO | disclosed |
| CN-118021957-A | MRNA for encoding anti-avian influenza H7N9 virus antibody and preparation method and application thereof | 深圳先进技术研究院 | 2024-05-14 | — | — | CN | disclosed |
| CN-118043466-A | Substitution of nucleotide bases in self-amplified mRNA | 葛兰素史克生物有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-118021956-A | MRNA for encoding anti-avian influenza H7N9 virus antibody and preparation method and application thereof | 深圳先进技术研究院 | 2024-05-14 | — | — | CN | disclosed |
| WO-2024097259-A1 | COMPOSITION AND METHODS FOR MRNA VACCINES AGAINST NOVEL OMICRON CORONAVIRUS INFECTIONS | RNAimmune, Inc. (US) | 2024-05-10 | — | — | WO | disclosed |
| CN-117964577-A | Cationic lipid compound, preparation method thereof, composition containing cationic lipid compound and application of cationic lipid compound | 天津全和诚生物技术有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117940158-A | Novel lipid nanoparticles comprising phosphatidylserine for nucleic acid delivery | 库瑞瓦格欧洲公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-117940118-A | Novel lipid nanoparticles for nucleic acid delivery | 库瑞瓦格欧洲公司 | 2024-04-26 | — | — | CN | disclosed |
| WO-2024078534-A1 | INTERFERING RNA FOR INHIBITING EXPRESSION OF MELANOPHILIN (MLPH) GENE, AND APPLICATION THEREOF | 北京键凯科技股份有限公司 | 2024-04-18 | — | — | WO | disclosed |
| EP-4351615-A2 | MULTIPLEXED TP53 AND PAN-RAS MRNA CANCER VACCINES | Rnaimmune, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| US-11952408-B2 | HPV-specific binding molecules | JUNO THERAPEUTICS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| CN-117731769-A | Nucleic acid vaccine for Varicella Zoster Virus (VZV) | 摩登纳特斯有限公司 | 2024-03-22 | — | — | CN | disclosed |
| EP-4334446-A1 | IMPROVED NUCLEIC ACID SEQUENCE FOR CELL TYPE SPECIFIC EXPRESSION | CureVac SE (DE) | 2024-03-13 | — | — | EP | disclosed |
| CN-117677847-A | Novel patentable regions in human cytomegalovirus glycoprotein B polypeptides and methods of use thereof | 辉瑞公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-117597144-A | Immunogenic compositions against influenza | 辉瑞公司 | 2024-02-23 | — | — | CN | disclosed |
| CN-117440824-A | RNA vaccine against SARS-CoV-2 variants | 库瑞瓦格欧洲公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-117377491-A | Immunogenic compositions | 葛兰素史克生物有限公司 | 2024-01-09 | — | — | CN | disclosed |
| US-11851690-B2 | Systems and methods for the treatment of hemoglobinopathies | EDITAS MEDICINE, INC. (US) | 2023-12-26 | — | — | US | disclosed |
| CN-117224710-A | Immunomodulatory therapeutic MRNA compositions encoding mutant peptides that activate oncogenes | 莫得纳特斯公司 | 2023-12-15 | — | — | CN | disclosed |
| CN-117222422-A | Sanopassing polypeptides and their use in the treatment of cancer | 旗舰创业创新五公司 | 2023-12-12 | — | — | CN | disclosed |
| EP-4284519-A1 | METHODS FOR TREATING AND AMELIORATING CANCER | The Regents of the University of California (US) | 2023-12-06 | — | — | EP | disclosed |
| CN-117159492-A | Lipid nanoparticle containing sialic acid lipid derivative and application thereof | 广州制高点医药科技有限公司 | 2023-12-05 | — | — | CN | disclosed |
| EP-4281560-A1 | METHODS FOR TREATING AND AMELIORATING CANCER | The Regents of the University of California (US) | 2023-11-29 | — | — | EP | disclosed |
| CN-117120020-A | Implantable medical device for delivery of nucleic acid encapsulated particles | 塞拉尼斯伊娃高性能聚合物公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-116917470-A | PAN-RAS mRNA cancer vaccine | 达冕生物有限公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-116916896-A | Method for preparing lipid nanoparticles | 摩登纳特斯有限公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-116837052-A | High-purity RNA composition and preparation method thereof | 摩登纳特斯有限公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-116829142-A | Methods for treating and ameliorating cancer | 加利福尼亚大学董事会 | 2023-09-29 | — | — | CN | disclosed |
| US-20230295725-A1 | COMPOSITIONS AND METHODS FOR TREATING CEP290-ASSOCIATED DISEASE | EDITAS MEDICINE, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| CN-116726203-A | Combination of MRNA encoding immunomodulatory polypeptides and uses thereof | 莫得纳特斯公司 | 2023-09-12 | — | — | CN | disclosed |
| WO-2023161350-A1 | NUCLEOTIDE DELIVERY OF CANCER THERAPY | IO BIOTECH APS (DK) | 2023-08-31 | — | — | WO | disclosed |
| EP-4228679-A1 | PAN-RAS MRNA CANCER VACCINES | Rnaimmune, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-4215543-A2 | HPV-SPECIFIC BINDING MOLECULES | Juno Therapeutics, Inc. (US) | 2023-07-26 | — | — | EP | disclosed |
| US-20230218578-A1 | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-07-13 | — | — | US | disclosed |
| CN-109476718-B | Combination of MRNA encoding immunomodulatory polypeptides and uses thereof | 莫得纳特斯公司 | 2023-07-04 | — | — | CN | disclosed |
| CN-109937253-B | High-purity RNA composition and preparation method thereof | 摩登纳特斯有限公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-116348131-A | Human cytomegalovirus gB polypeptides | 辉瑞公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-116322788-A | Cyclic RNA compositions and methods | 奥纳治疗公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-116322758-A | Nucleic acid-based combination vaccine | 库尔维科欧洲股份公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-116133652-A | Method for preparing lipid nanoparticles | 摩登纳特斯有限公司 | 2023-05-16 | — | — | CN | disclosed |
| CN-116113430-A | Coronavirus vaccine | 奎尔法克股份有限公司 | 2023-05-12 | — | — | CN | disclosed |
| CN-116033920-A | Large sequence pan coronavirus vaccine composition | 加利福尼亚大学董事会 | 2023-04-28 | — | — | CN | disclosed |
| WO-2023064907-A1 | COMPOSITIONS AND METHODS FOR VACCINATION AGAINST PATHOGENIC CORONAVIRUS SPECIES AND VARIANTS | YALE UNIVERSITY (US) | 2023-04-20 | — | — | WO | disclosed |
| CN-115803049-A | Antigen encoding cassette | 磨石生物公司 | 2023-03-14 | — | — | CN | disclosed |
| WO-2023031392-A2 | NOVEL LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS COMPRISING PHOSPHATIDYLSERINE | CureVac SE (DE) | 2023-03-09 | — | — | WO | disclosed |
| CN-115768437-A | Capping compounds, compositions and methods of use thereof | 磨石生物公司 | 2023-03-07 | — | — | CN | disclosed |
| WO-2023018831-A2 | COMPOSITION AND METHODS OF MRNA VACCINES AGAINST NOVEL CORONAVIRUS INFECTION | RNAimmune, Inc. (US) | 2023-02-16 | — | — | WO | disclosed |
| US-20230038993-A1 | COMPOSITIONS AND METHODS FOR TREATING CEP290-ASSOCIATED DISEASE | EDITAS MEDICINE, INC. (US) | 2023-02-09 | — | — | US | disclosed |
| EP-4126030-A1 | MULTILAMELLAR RNA NANOPARTICLE VACCINE AGAINST SARS-COV-2 | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-02-08 | — | — | EP | disclosed |
| EP-4123024-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING HERPES SIMPLEX VIRUS TYPE 1 (HSV-1) | Editas Medicine, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| CN-115516090-A | TREM compositions and uses thereof | 旗舰先锋创新VI有限责任公司 | 2022-12-23 | — | — | CN | disclosed |
| CN-115485372-A | Host defense suppression methods and compositions for regulating genomes | 旗舰先锋创新VI有限责任公司 | 2022-12-16 | — | — | CN | disclosed |
| WO-2022261514-A2 | MULTIPLEXED TP53 AND PAN-RAS MRNA CANCER VACCINES | RNAimmune, Inc. (US) | 2022-12-15 | — | — | WO | disclosed |
| CN-113151312-B | Novel coronavirus SARS-CoV-2mRNA vaccine and its preparation method and application | 中国科学院微生物研究所 | 2022-12-09 | — | — | CN | disclosed |
| CN-115397984-A | Recombinase compositions and methods of use | 旗舰先锋创新VI有限责任公司 | 2022-11-25 | — | — | CN | disclosed |
| EP-4047092-A1 | CAS9 FUSION MOLECULES, GENE EDITING SYSTEMS, AND METHODS OF USE THEREOF | Editas Medicine, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| WO-2022165398-A1 | METHODS FOR TREATING AND AMELIORATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | WO | disclosed |
| US-20220218750-A1 | CELLS EXPRESSING A CHIMERIC RECEPTOR FROM A MODIFIED CD247 LOCUS, RELATED POLYNUCLEOTIDES AND METHODS | JUNO THERAPEUTICS, INC. (US) | 2022-07-14 | — | — | US | disclosed |
| EP-4019635-A1 | CRISPR/CAS-RELATED METHODS, COMPOSITIONS AND COMPONENTS | Editas Medicine, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| EP-4019975-A1 | EVALUATION OF CAS9 MOLECULE/GUIDE RNA MOLECULE COMPLEXES | Editas Medicine, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| EP-3498845-B1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING HERPES SIMPLEX VIRUS TYPE 1 (HSV-1) | EDITAS MEDICINE INC (US) | 2022-06-22 | — | — | EP | disclosed |
| US-20220135970-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING USHER SYNDROME AND RETINITIS PIGMENTOSA | EDITAS MEDICINE, INC. (US) | 2022-05-05 | — | — | US | disclosed |
| CN-114404581-A | Cancer vaccine | 摩登纳特斯有限公司 | 2022-04-29 | — | — | CN | disclosed |
| WO-2022081764-A1 | PAN-RAS mRNA CANCER VACCINES | RNAimmune, Inc. (US) | 2022-04-21 | — | — | WO | disclosed |
| CN-114272369-A | mRNA vaccine composition for preventing varicella-zoster virus | 中国科学院微生物研究所 | 2022-04-05 | — | — | CN | disclosed |
| US-20220073951-A1 | SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | EDITAS MEDICINE, INC. | 2022-03-10 | — | — | US | disclosed |
| EP-3957735-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING USHER SYNDROME AND RETINITIS PIGMENTOSA | Editas Medicine, Inc. (US) | 2022-02-23 | — | — | EP | disclosed |
| EP-3443086-B1 | CAS9 FUSION MOLECULES, GENE EDITING SYSTEMS, AND METHODS OF USE THEREOF | EDITAS MEDICINE INC (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3893909-A2 | KRAS VARIANT MRNA MOLECULES | CureVac AG (DE) | 2021-10-20 | — | — | EP | disclosed |
| WO-2021202772-A1 | MULTILAMELLAR RNA NANOPARTICLE VACCINE AGAINST SARS-COV-2 | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2021-10-07 | — | — | WO | disclosed |
| WO-2021195136-A2 | DEVICES FOR DETECTING ANTIBODIES TO CORONAVIRUS ANTIGENS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-09-30 | — | — | WO | disclosed |
| EP-3286571-B1 | EVALUATION OF CAS9 MOLECULE/GUIDE RNA MOLECULE COMPLEXES | EDITAS MEDICINE INC (US) | 2021-08-18 | — | — | EP | disclosed |
| US-20200263206-A1 | TARGETED INTEGRATION SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | EDITAS MEDICINE, INC. (US) | 2020-08-20 | — | — | US | disclosed |
| WO-2020123300-A2 | KRAS VARIANT MRNA MOLECULES | ELI LILLY AND COMPANY (US) | 2020-06-18 | — | — | WO | disclosed |
| US-20200157515-A1 | SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | EDITAS MEDICINE, INC. | 2020-05-21 | — | — | US | disclosed |
| US-20200056164-A1 | ENGINEERED CAS9 NUCLEASES | EDITAS MEDICINE, INC. | 2020-02-20 | — | — | US | disclosed |
| EP-3532070-A1 | MESSENGER RIBONUCLEIC ACIDS FOR ENHANCING IMMUNE RESPONSES AND METHODS OF USE THEREOF | Modernatx, Inc. (US) | 2019-09-04 | — | — | EP | disclosed |
| EP-3116997-B1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING LEBER'S CONGENITAL AMAUROSIS 10 (LCA10) | EDITAS MEDICINE INC (US) | 2019-05-15 | — | — | EP | disclosed |
| WO-2018081459-A9 | MESSENGER RIBONUCLEIC ACIDS FOR ENHANCING IMMUNE RESPONSES AND METHODS OF USE THEREOF | MODERNATX, INC. (US) | 2018-11-22 | — | — | WO | disclosed |
| EP-3386484-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS | ModernaTX, Inc. (US) | 2018-10-17 | — | — | EP | disclosed |
| EP-3364982-A2 | SEXUALLY TRANSMITTED DISEASE VACCINES | ModernaTX, Inc. (US) | 2018-08-29 | — | — | EP | disclosed |
| WO-2018081459-A1 | MESSENGER RIBONUCLEIC ACIDS FOR ENHANCING IMMUNE RESPONSES AND METHODS OF USE THEREOF | MODERNATX, INC. (US) | 2018-05-03 | — | — | WO | disclosed |
| EP-3066201-B1 | CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING GRNAS | EDITAS MEDICINE INC (US) | 2018-03-07 | — | — | EP | disclosed |
| WO-2017099823-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2017-06-15 | — | — | WO | disclosed |
| WO-2017070616-A2 | SEXUALLY TRANSMITTED DISEASE VACCINES | MODERNATX, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| US-9573882-B2 | Use of 4-[ethyl(dimethyl)ammonio]butanoate in the treatment of cardiovascular disease | JSC GRINDEKS (LV) | 2017-02-21 | — | — | US | disclosed |
| US-20160137589-A1 | USE OF 4-[ETHYL(DIMETHYL)AMMONIO]BUTANOATE IN THE TREATMENT OF CARDIOVASCULAR DISEASE | JSC GRINDEKS (LV) | 2016-05-19 | — | — | US | disclosed |
| US-9278907-B2 | Use of 4-[ethyl(dimethyl)ammonio]butanoate in the treatment of cardiovascular disease | JSC GRINDEKS (LV) | 2016-03-08 | — | — | US | disclosed |
| EP-2491005-B1 | USE OF 4-[ETHYL(DIMETHYL)AMMONIO]BUTANOATE IN THE TREATMENT OF CARDIOVASCULAR DISEASE | GRINDEKS JSC (LV) | 2014-07-23 | — | — | EP | disclosed |
| CN-102666476-B | Use of 4-[ethyl(dimethyl)ammonio]butanoate in the treatment of cardiovascular disease | GRINDEKS JOINT STOCK COMPANY | 2014-07-09 | — | — | CN | disclosed |
| CN-103547562-A | 4- [ (haloalkyl) (dimethyl) ammonio ] butanoates and their use in the treatment of cardiovascular disease | JSC GRINDEKS | 2014-01-29 | — | — | CN | disclosed |
| CN-102666476-A | Use of 4-[ethyl(dimethyl)ammonio]butanoate in the treatment of cardiovascular disease | GRINDEKS JSC | 2012-09-12 | — | — | CN | disclosed |
| US-20120220656-A1 | USE OF 4-[ETHYL(DIMETHYL)AMMONIO]BUTANOATE IN THE TREATMENT OF CARDIOVASCULAR DISEASE | JSC GRINDEKS (LV) | 2012-08-30 | — | — | US | disclosed |
| EP-2491005-A1 | USE OF 4-[ETHYL(DIMETHYL)AMMONIO]BUTANOATE IN THE TREATMENT OF CARDIOVASCULAR DISEASE | Grindeks, A Joint Stock Company (LV) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011048201-A1 | USE OF 4-[ETHYL(DIMETHYL)AMMONIO]BUTANOATE IN THE TREATMENT OF CARDIOVASCULAR DISEASE | GRINDEKS, A JOINT STOCK COMPANY (LV) | 2011-04-28 | — | — | WO | disclosed |
| EP-1490326-B1 | METHOD FOR PRODUCING (METH)ACRYLIC ACID ESTERS | BASF SE (DE) | 2010-12-29 | — | — | EP | disclosed |
| CN-100579976-C | p38 inhibitors and methods of their use | ARRAY BIOPHARMA INC | 2010-01-13 | — | — | CN | disclosed |
| CN-1784396-A | p38 inhibitors and methods of their use | ARRAY BIOPHARMA INC (US) | 2006-06-07 | — | — | CN | disclosed |
| EP-1490326-A2 | METHOD FOR PRODUCING (METH)ACRYLIC ACID ESTERS | BASF AKTIENGESELLSCHAFT (DE) | 2004-12-29 | — | — | EP | disclosed |
| WO-2002100817-A2 | METHOD FOR PRODUCING (METH)ACRYLIC ACID ESTERS | BASF AKTIENGESELLSCHAFT (DE) | 2002-12-19 | — | — | WO | disclosed |
| US-5851681-A | Wiring structure with metal wiring layers and polyimide layers, and fabrication process of multilayer wiring board | HITACHI, LTD. (JP) | 1998-12-22 | — | — | US | disclosed |
| US-5610315-A | Process for the preparation of 6,7-diacyl-7-deacetylforskolin derivatives | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1997-03-11 | — | — | US | disclosed |
| US-5484954-A | HEATING, DEACYLATING | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1996-01-16 | — | — | US | disclosed |
| US-5302730-A | Acylation with acetic acid at positions one and seven; eliminating acyl group at position seven by solvolysis | NIPPON KAYAKU KK (JP) | 1994-04-12 | — | — | US | disclosed |
| EP-0297496-B1 | Novel process for the preparation of 6,7-Diacyl-7-deacetylforskolin derivatives | NIPPON KAYAKU KK (JP) | 1994-01-19 | — | — | EP | disclosed |
| CN-1016869-B | Process for preparing 6, 7-diacyl-7-deacetylforskolin derivatives | NIPPON KAYAKU KK (JP) | 1992-06-03 | — | — | CN | disclosed |
| CN-1030583-A | Preparation 6,7-diacyl-7-takes off the novel method of acetyl forskrine derivant | NIPPON KAYAKU KK (JP) | 1989-01-25 | — | — | CN | disclosed |
| EP-0297496-A2 | Novel process for the preparation of 6,7-Diacyl-7-deacetylforskolin derivatives | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1989-01-04 | — | — | EP | disclosed |
| EP-0297496-A2 | Novel process for the preparation of 6,7-Diacyl-7-deacetylforskolin derivatives | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1989-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137589-A1 | USE OF 4-[ETHYL(DIMETHYL)AMMONIO]BUTANOATE IN THE TREATMENT OF CARDIOVASCULAR DISEASE | FABP3, ABAT, BBOX1 | GABRR1 325/4885CYP1A2 543/4885BLM 3185/4885 |
| US-20230218578-A1 | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | C9, C5, C1QBP | GABRR1 1256/4885CYP1A2 112/4885BLM 883/4885 |
| US-11851690-B2 | Systems and methods for the treatment of hemoglobinopathies | HBG2, HBG1, HBB | GABRR1 1287/4885CYP1A2 3272/4885BLM 1894/4885 |
| US-20230038993-A1 | COMPOSITIONS AND METHODS FOR TREATING CEP290-ASSOCIATED DISEASE | CLN6, CEP170, COPB1 | GABRR1 1412/4885CYP1A2 4812/4885BLM 1130/4885 |
| US-12031132-B2 | Systems and methods for the treatment of hemoglobinopathies | HBG2, HBG1, HBB | GABRR1 1287/4885CYP1A2 3272/4885BLM 1894/4885 |
| US-20220135970-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING USHER SYNDROME AND RETINITIS PIGMENTOSA | NR2E3, RB1, ALDH1A2 | GABRR1 2065/4885CYP1A2 4697/4885BLM 700/4885 |
| US-20120220656-A1 | USE OF 4-[ETHYL(DIMETHYL)AMMONIO]BUTANOATE IN THE TREATMENT OF CARDIOVASCULAR DISEASE | FABP3, ABAT, BBOX1 | GABRR1 325/4885CYP1A2 543/4885BLM 3185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.